卡铂-话题@MedSci

#卡铂#

64篇内容 | 1408人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1396331, encodeId=f501139633142, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, objectType=article, longId=736047, objectId=95aee36047ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95aee36047ae, replyNumber=0, likeNumber=46, createdTime=2022-08-18, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95aee36047ae, moduleTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95aee36047ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396330, encodeId=c4c8139633020, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=顺铂、卡铂、奥沙利铂......5种铂类药物有何区别？超全盘点！, objectType=article, longId=726498, objectId=feefe264980b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=feefe264980b, replyNumber=0, likeNumber=55, createdTime=2022-05-11, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=feefe264980b, moduleTitle=顺铂、卡铂、奥沙利铂......5种铂类药物有何区别？超全盘点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=feefe264980b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396329, encodeId=ab3c1396329f7, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=AACR 2022：Adebrelimab或安慰剂加卡铂和依托泊苷作为广泛期SCLC的一线治疗, objectType=article, longId=724031, objectId=ca16e2403181, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca16e2403181, replyNumber=0, likeNumber=60, createdTime=2022-04-13, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca16e2403181, moduleTitle=AACR 2022：Adebrelimab或安慰剂加卡铂和依托泊苷作为广泛期SCLC的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca16e2403181)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396328, encodeId=f7cc1396328f4, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效, objectType=article, longId=301524, objectId=dfda301524c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfda301524c5, replyNumber=0, likeNumber=48, createdTime=2022-03-25, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfda301524c5, moduleTitle=Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfda301524c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396327, encodeId=94eb139632ed3, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, objectType=article, longId=299451, objectId=fc31299451e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31299451e9, replyNumber=0, likeNumber=62, createdTime=2022-02-24, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31299451e9, moduleTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31299451e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396326, encodeId=66a01396326e7, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, objectType=article, longId=295703, objectId=ea9c295e0337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea9c295e0337, replyNumber=0, likeNumber=38, createdTime=2022-02-17, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea9c295e0337, moduleTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea9c295e0337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396325, encodeId=7a4d1396325e1, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, objectType=article, longId=295073, objectId=a9a02950e37b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9a02950e37b, replyNumber=0, likeNumber=37, createdTime=2022-02-04, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9a02950e37b, moduleTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9a02950e37b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396324, encodeId=1785139632490, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, objectType=article, longId=294716, objectId=db94294e16ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db94294e16ed, replyNumber=0, likeNumber=0, createdTime=2022-01-27, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db94294e16ed, moduleTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db94294e16ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396323, encodeId=ce07139632350, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, objectType=article, longId=292260, objectId=b801292260d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b801292260d3, replyNumber=0, likeNumber=30, createdTime=2021-12-21, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b801292260d3, moduleTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b801292260d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396322, encodeId=839813963223f, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=BMC Cancer：顺铂加依托泊苷(EP) vs卡铂加依托泊苷(EC)治疗广泛期SCLC的疗效和安全性, objectType=article, longId=291846, objectId=80082918465c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80082918465c, replyNumber=0, likeNumber=31, createdTime=2021-12-16, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80082918465c, moduleTitle=BMC Cancer：顺铂加依托泊苷(EP) vs卡铂加依托泊苷(EC)治疗广泛期SCLC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80082918465c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396321, encodeId=05941396321ba, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌, objectType=article, longId=221752, objectId=5171221e521f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5171221e521f, replyNumber=0, likeNumber=43, createdTime=2021-12-10, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5171221e521f, moduleTitle=Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5171221e521f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396320, encodeId=e2bf1396320b0, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, objectType=article, longId=221315, objectId=ce4a22131527, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4a22131527, replyNumber=0, likeNumber=58, createdTime=2021-12-01, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4a22131527, moduleTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4a22131527)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396319, encodeId=50d61396319be, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, objectType=article, longId=219629, objectId=09d321962921, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09d321962921, replyNumber=0, likeNumber=50, createdTime=2021-11-03, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09d321962921, moduleTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09d321962921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396318, encodeId=8184139631835, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Clin Cancer Res：抗集落刺激因子单克隆抗体Lacnotuzumab联合吉西他滨-卡铂治疗三阴性乳腺癌的疗效, objectType=article, longId=218488, objectId=28cf21848858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28cf21848858, replyNumber=0, likeNumber=0, createdTime=2021-10-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28cf21848858, moduleTitle=Clin Cancer Res：抗集落刺激因子单克隆抗体Lacnotuzumab联合吉西他滨-卡铂治疗三阴性乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28cf21848858)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396317, encodeId=3546139631e03, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Int J Cancer：多西他赛+卡铂 vs 表阿霉素+环磷酰胺续贯多西他赛新辅助化疗治疗早期三阴型乳腺癌的疗效对比：多中心随机对照研究(NeoCART), objectType=article, longId=218117, objectId=5c0921811e5f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c0921811e5f, replyNumber=0, likeNumber=40, createdTime=2021-10-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c0921811e5f, moduleTitle=Int J Cancer：多西他赛+卡铂 vs 表阿霉素+环磷酰胺续贯多西他赛新辅助化疗治疗早期三阴型乳腺癌的疗效对比：多中心随机对照研究(NeoCART), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c0921811e5f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396316, encodeId=f30f1396316e3, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效, objectType=article, longId=217313, objectId=046121e3130e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=046121e3130e, replyNumber=0, likeNumber=45, createdTime=2021-09-20, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=046121e3130e, moduleTitle=J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=046121e3130e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396315, encodeId=b383139631599, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果, objectType=article, longId=216406, objectId=13bc21640686, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13bc21640686, replyNumber=0, likeNumber=44, createdTime=2021-08-29, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13bc21640686, moduleTitle=J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13bc21640686)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396314, encodeId=28ae1396314a4, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤, objectType=article, longId=215909, objectId=bd1421590942, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd1421590942, replyNumber=0, likeNumber=46, createdTime=2021-08-19, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd1421590942, moduleTitle=Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd1421590942)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396313, encodeId=1276139631301, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性, objectType=article, longId=214609, objectId=4c4421460961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c4421460961, replyNumber=0, likeNumber=0, createdTime=2021-07-23, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c4421460961, moduleTitle=Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c4421460961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396312, encodeId=c0c0139631200, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, objectType=article, longId=213326, objectId=17162133260e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17162133260e, replyNumber=0, likeNumber=41, createdTime=2021-06-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17162133260e, moduleTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17162133260e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卡铂

2020-05-29

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌

2022-08-18

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

顺铂、卡铂、奥沙利铂......5种铂类药物有何区别？超全盘点！

2022-05-11

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

AACR 2022：Adebrelimab或安慰剂加卡铂和依托泊苷作为广泛期SCLC的一线治疗

2022-04-13

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效

2022-03-25

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效

2022-02-24

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效

2022-02-17

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性

2022-02-04

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）

2022-01-27

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效

2021-12-21

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

BMC Cancer：顺铂加依托泊苷(EP) vs卡铂加依托泊苷(EC)治疗广泛期SCLC的疗效和安全性

2021-12-16

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌

2021-12-10

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌

2021-12-01

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者

2021-11-03

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Clin Cancer Res：抗集落刺激因子单克隆抗体Lacnotuzumab联合吉西他滨-卡铂治疗三阴性乳腺癌的疗效

2021-10-14

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Int J Cancer：多西他赛+卡铂 vs 表阿霉素+环磷酰胺续贯多西他赛新辅助化疗治疗早期三阴型乳腺癌的疗效对比：多中心随机对照研究(NeoCART)

2021-10-06

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效

2021-09-20

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果

2021-08-29

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤

2021-08-19

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性

2021-07-23

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性

2021-06-28

科室
- - 订阅+
  - 更多科室
工具
服务